Genscript Biotech (1548.HK) Azione Prezzo
Genscript Biotech Prezzo
Il fatturato è cresciuto a un tasso composto del 25,0% annuo negli ultimi 13 anni, raggiungendo 959,53 Mio. USD. L'utile per azione è cresciuto del 41,7% all'anno negli ultimi 11 anni. Il margine netto di Genscript Biotech si attesta al -55,5%, in aumento rispetto al -68,1% di alcuni anni fa. Genscript Biotech offre attualmente un rendimento da dividendo di circa il 0,22%. Il payout ratio è pari a circa il 10% degli utili. Gli analisti fissano un target di prezzo mediano di 2,53 USD, ovvero il 53,2% sotto il prezzo attuale. Su 16 analisti, 15 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Genscript Biotech Prezzo delle azioni
Genscript Biotech Azione e analisi azionaria
Domande frequenti sull'azione Genscript Biotech
The business model of Genscript Biotech Corp focuses on providing integrated solutions for life sciences research and drug discovery. The company offers a comprehensive range of products and services, including gene synthesis, protein expression, antibody development, and molecular diagnostics. Genscript Biotech Corp aims to accelerate biological research and development by providing high-quality and cost-effective solutions to scientists worldwide. Through its innovative technologies and expertise, the company has gained a strong reputation in the biotech industry. Genscript Biotech Corp continually strives to enhance its capabilities and expand its product portfolio to meet the evolving needs of the scientific community.
Genscript Biotech Corp is primarily active in the biotechnology industry.
The main competitors of Genscript Biotech Corp in the market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Sartorius AG.
Genscript Biotech Corp is a leading biotechnology company with a rich history and background. Established in 2002, the company specializes in providing high-quality services and products in the field of life sciences research. Genscript is dedicated to enabling advancements in scientific discoveries and breakthroughs through its expertise in gene synthesis, custom protein production, antibody development, and many other gene-related services. With its state-of-the-art facilities and a global customer base, Genscript has become a trusted partner for researchers and pharmaceutical companies worldwide. The company's commitment to innovation and excellence has helped propel it to the forefront of the biotech industry, making Genscript Biotech Corp a reliable choice for investors seeking opportunities in this dynamic sector.
Genscript Biotech Corp has achieved several significant milestones. As a leading biotechnology company, Genscript has made remarkable strides in the field. Notably, the company successfully completed the genome synthesis of the E. coli bacterium in 2010, which was a groundbreaking achievement. In 2015, Genscript became the first Chinese biotech firm to be listed on the Hong Kong Stock Exchange, marking a significant milestone for the company. Moreover, Genscript has continuously expanded its portfolio of services and products, catering to various research areas and providing innovative solutions to the scientific community. With such achievements, Genscript Biotech Corp stands as a prominent player in the biotech industry.
Genscript Biotech Corp is primarily present in several countries and regions across the globe. The company has a strong foothold in China, where its headquarters are located. Additionally, Genscript Biotech Corp has a significant presence in the United States, with offices and operations spread across various states. The company has also established a strong international presence, with operations and collaborations in Europe, Asia, and other regions worldwide. With its global reach, Genscript Biotech Corp continues to expand its presence and deliver innovative solutions in the field of biotechnology.
Genscript Biotech Corp represents values of innovation, collaboration, and commitment to scientific advancement. With a strong corporate philosophy centered around providing quality products and services, Genscript strives to enhance the understanding and application of biotechnology worldwide. The company is dedicated to delivering cutting-edge research tools, custom solutions, and high-quality services to enable scientists and researchers in various fields. Genscript Biotech Corp aims to foster a culture of excellence, integrity, and customer-centricity, positioning itself as a global leader in the biotech industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 2,67 USD per l’azione Genscript Biotech (mediana: 2,53 USD), pari a -50,5 % rispetto all’ultimo prezzo. Il consenso si basa su 16 giudizi di analisti.
16 analisti valutano attualmente l’azione Genscript Biotech: 15 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Genscript Biotech ricavi pari a 895,51 Mio. USD e un utile per azione di 0,01 USD.
Convertita al tasso di cambio attuale, l’azione Genscript Biotech quota 4,82 EUR (5,40 USD).
L’azione Genscript Biotech (1548.HK) è quotata su 4 borse, tra cui: Hongkong (HKEX) (1548.HK), Frankfurt (G51.F), München (G51.MU).
GenScript Biotech Corp is a leading company in the biotech industry that specializes in the development and manufacture of high-quality biological products and services. The company offers a wide range of products and services, including DNA synthesis, protein production, antibody production, cell line development, and diagnostic tools. The company's divisions include proprietary products, manufacturing, and CRO (Contract Research Organization). Proprietary products contribute a large portion of the company's revenue and include various products such as CRISPR/Cas9 kits, DNA sequencing, protein analysis, and antibody services. GenScript Biotech's manufacturing business model is highly tailored to customer needs. It is based on critical procedures that incorporate proven expertise and patented technologies. The model includes a targeted approach to developing the necessary production processes, quality controls at every step of the manufacturing process, and support throughout the customer's entire lifecycle. An essential goal of the company is to support customers in every phase of the manufacturing process to ensure smooth and successful production. The Contract Research Organization (CRO) division of GenScript Biotech focuses on supporting customers in early stages of biological research or clinical trials. Through partnerships with the company, customers are supported through services such as protein engineering, cell line development, cell therapy, in vivo services, and pharmaceutical development. The company also offers a variety of diagnostic solutions and laboratory services. Examples include the development of cellular assays, reagent manufacturing, and DNA sequencing services. Overall, GenScript Biotech Corp is strongly focused on providing rapid and flexible service to its customers by offering a wide range of biopharmaceuticals, diagnostic tools, and laboratory services. The company has a global presence with offices in China, the USA, Europe, Japan, and Singapore. As a company that prioritizes innovation and quality, GenScript Biotech holds a strong position in the biotechnology market. With its various divisions and high-quality offering of products and services, the company provides its customers with a valuable partner to achieve their goals in biotechnology.
Il attesa fatturato di Genscript Biotech ammonta a 895,51 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Genscript Biotech ammonta a 13,77 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Genscript Biotech è attualmente 874,49. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Genscript Biotech.
Il rapporto prezzo/fatturato (P/S) di Genscript Biotech è attualmente 13,44. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Genscript Biotech.
Il Quality Score AlleAktien per Genscript Biotech è 5/10.
L'ISIN di Genscript Biotech è KYG3825B1059. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Genscript Biotech è A2ACSB. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Genscript Biotech è 1548.HK. Con questo simbolo di borsa vengono negoziate le azioni Genscript Biotech in borsa.
Azione Genscript Biotech
Gruppo di pari di Genscript Biotech
Genscript Biotech Ticker
Genscript Biotech FIGI
Altre metriche e analisi di Genscript Biotech in Deep Dive.
La nostra analisi azionaria dell'azione Genscript Biotech include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Genscript Biotech. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: